The roles and mechanisms of miRNA in HBV-HCC carcinogenesis: Why no therapeutic agents after 30 years?
KURT SARTORIUS1,2,3,*, BENN SARTORIUS4, CHERIE WINKLER5, ANIL CHUTURGOON2, ANNA KRAMVIS1, PING AN5, WEIGANG ZHANG6, YUNJIE LU3,6,7,*
BIOCELL, Vol.48, No.11, pp. 1543-1567, 2024, DOI:10.32604/biocell.2024.055505
- 07 November 2024
(This article belongs to the Special Issue: Non-coding RNAs (ncRNAs) in Human Diseases)
Abstract Hepatitis B-associated hepatocellular carcinoma (HBV-HCC) remains an intractable high-mortality solid tumor cancer that accounted for 42% of global HCC cases in 2019. Despite some developments in systemic therapy, only a small subset of late-stage HCC patients responds positively to recently developed therapeutic innovations. MicroRNAs (miRNAs) act as an ancillary epigenetic system that can regulate genome expression in all cancer pathways including HCC. The molecular mechanisms of miRNA regulation in cancer pathogenesis offered researchers a new approach that was widely hoped would translate into miRNA-based drugs and diagnostics. Thirty years on, miRNA-based diagnostic and therapeutic agents… More >